Rubella virus causes a mild disease; however, infection during the first trimester of pregnancy may lead to congenital rubella syndrome (CRS) in over 80% of affected pregnancies. Vaccination is recommended and has been shown to effectively reduce CRS incidence. Uganda plans to introduce routine rubella vaccination in 2019. The World Health Organization recommends assessing the disease burden and obtaining the baseline molecular virological data before vaccine introduction. Sera collected during case-based measles surveillance from January 2005 to July 2018 were tested for rubella immunoglobulin M (IgM) antibodies. Sera from confirmed rubella outbreaks from January 2012 to August 2017 were screened using real-time reverse-transcription polymerase chain reaction (RT-PCR); for positive samples, a region within the E1 glycoprotein coding region was amplified and sequenced. Of the 23 196 suspected measles cases serologically tested in parallel for measles and rubella, 5334 (23%) were rubella IgM-positive of which 2710 (50.8%) cases were females with 2609 (96.3%) below 15 years of age. Rubella IgM-positive cases were distributed throughout the country and the highest number was detected in April, August, and November. Eighteen (18%) of the 100 sera screened were real-time RT-PCR-positive of which eight (44.4%) were successfully sequenced and genotypes 1G and 2B were identified. This study reports on the seroprevalence and molecular epidemiology of rubella. Increased knowledge of former and current rubella viruses circulating in Uganda will enhance efforts to monitor the impact of vaccination as Uganda moves toward control and elimination of rubella and CRS.
knowledge of the burden of rubella in the country is limited to only two studies. 8, 9 With such limited published data, the trends of rubella incidence in the country are not available for program use and the impact after vaccine introduction may be poorly estimated because of the lack of baseline data.
Collection of specific specimens for molecular virological data is challenging as it requires timely collection of throat swab and oral fluid specimens by experienced personnel and a stringent reverse cold chain.
These requirements are often hard to achieve through the routine surveillance for measles and rubella. Alternative samples such as serum have been shown to provide molecular virological data retrospectively 10, 11 and are a potential source of baseline data on the genetic diversity of the rubella viruses in the prevaccine era. Rubella virus RNA may be detected in acute phase serum specimens (0-3 days from rash onset) that are rubella IgM-positive by using the polymerase chain reaction and positive samples can be genotyped. 10, 11 We report on the rubella disease burden from January 2005 to July 2018 using case-based measles surveillance data as well as the molecular virological data using archived serum samples from confirmed rubella outbreaks from January 2012 to August 2017. This documentation will provide baseline information on the epidemiology of rubella before rubella vaccine introduction in Uganda.
| MATERIALS AND METHODS
The Regional Measles Reference laboratory in Uganda has been a member of the Global WHO Measles and Rubella Laboratory Network 12 since 2000 and the rubella cases in this study were identified through measles case-based surveillance following guidelines provided by the WHO Regional Office for Africa. 13 Based on these guidelines, a suspected measles case is defined as "any person with generalized maculopapular rash and fever plus one of the following, cough or coryza (runny nose) or conjunctivitis (red eyes) or any person in whom a clinician suspects measles." Individuals fitting these criteria and who presented at health facilities within 30 days of rash onset were investigated using a standard case investigation form for demographic and clinical history data and a serum specimen collected for laboratory analysis. When five or more cases were investigated in a health facility or district in a month, this was classified as a suspected outbreak. Specimens were transported to the laboratory under cold chain. For the 2nd round, 1 µl of the 1st round PCR product was used with the primers in Table 1 and the initial transcription step eliminated from the cycling conditions. The resulting products were purified using the ExoSAP-IT PCR Product Cleanup Reagent (Thermo Fisher Scientific, Carlsbad, CA).
| Enzyme-linked immunosorbent assay
Briefly, 5 µl of the PCR product was mixed with 2 µl of the enzyme and incubated at 37°C for 4 minutes followed by a 1-minute incubation at 80°C in a thermal cycler. The 739-nt sequences required for the genotyping of rubella viruses were determined bidirectionally with an Applied Biosystems Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Austin, TX) and a 3500 DNA sequencer (Applied Biosystems, Japan). To cover the sequence of the 739-nt region, the primers from the second round PCR and two internal primers (8945F and 9112R 9 ) were used.
| Phylogenetic analyses
Analyses of the sequences were performed using Sequencher version 4.10.1 (Gene Codes Corporation, Ann Arbor, MI) and the genotypes determined by comparison with the 32 WHO rubella virus reference sequences. 15 Sublineage reference sequences (rubella virus genetic grouping nomenclature proposed by Rivailler et al 16 ) were retrieved from the GenBank using the BLAST program in NCBI. All study sequences, WHO reference sequences and sublineage reference sequences were aligned using the ClustalW alignment program within the Molecular Evolutionary Genetics Analysis (MEGA7) software. 17 The phylogenetic trees were inferred using the maximum likelihood method based on the Tamura-Nei model. The robustness of the nodes was tested with 1000 bootstrap replications and bootstrap support values greater than 75 are shown at the nodes. Rubella sequence data from this study were deposited in the GenBank with the accession numbers MK399390-MK399397.
| Epidemiological analyses
All the data obtained, that is, both demographic and laboratory results were entered in an electronic database. The districts were grouped into the administrative regions as provided by the Uganda (11) 31 (22) 120 (69) 36 (16) 32 (17) 20 (13) ≥15 (179 (101)) 12 (06)
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| Rubella virus sequence distribution and phylogenetic analysis
Of the 100 sera tested at CDC, 18 were positive by real-time PCR. For eight of these, the 739-nt window of the E1 glycoprotein was successfully amplified and sequenced. Two genotypes were detected, 1G (three sequences) and 2B (five sequences). The majority of these (5 out of 8;
62.5%) were obtained from cases whose serum had been collected within a day of rash onset. Genotype 1G was detected in 2012 and 2016 and genotype 2B in 2014, 2015, and 2017 ( Table 3 ). The Western and Eastern regions had both genotypes 1G and 2B, the Northern region had genotype 2B and the Central region had none detected.
Phylogenetic analysis of the study sequences along with WHO rubella reference sequences and rubella sublineage reference sequences proposed by Rivailler et al 16 showed the genotype 1G sequences belonged to sublineage 1G-L2b and the genotype 2B sequences belonged to sublineage 2B-L2c (Figure 3 ).
| DISCUSSION
The present study documents that rubella in Uganda is a childhood disease affecting mainly those below 15 years of age. This is in agreement with previously published findings. 4, [18] [19] [20] [21] However, because the immunization program mainly targets those under 5 years of age, and current surveillance is focused on measles, under-reporting may be high among those older than 5 years. Also, HIV-infected infants, because of their defective cell-mediated immunity, may not develop the characteristic measles like rash 22, 23 which is the basis for the clinical diagnosis of measles (and inadvertently the diagnosis of rubella)
according to the WHO standard case definition. 13 Furthermore, 20%
to 50% of all rubella infections are subclinical. 3 The majority of the females who were rubella IgM-positive were under the reproductive age of 15 years. This is similar to what was reported in Ethiopia, Cameroon, Zimbabwe, and Central African 
| 283
Republic. [18] [19] [20] [21] 24 This very likely leads to immunity during child- of women in the same age group had already given birth while 5%
were pregnant with their first child. 25 The highest number of rubella IgM-positive cases was seen in the months of April, August, and November (Figure 2 ). Uganda has a tropical climate with a bimodal rainfall pattern characterized by rains in the months of March to May and October to December with the remaining months being generally dry with limited rainfall. 28 April and November, noted to have the highest number of rubella IgMpositives, are months characterized by rains. This is contrary to what was been reported in Zimbabwe where the highest number was seen in the late spring months (October to November) which are generally dry. 20 Although the rainfall patterns may differ between the two countries, the months with the highest prevalence, that is, March/ April and October/November are similar in many years. Also, it is interesting to note is that the rubella incidence appears to be very low for both countries in 2009 and most of 2010 (until October). This pattern suggests a multiyear cycle for rubella in the two countries.
Combined data from the current and a previous report of rubella in Uganda support a 3-to 4-year rubella cycle in Uganda. 8 21.5% RT-PCR positive and 7.5% genotyped) providing additional evidence that this is an effective method for retrospective genotype baseline determination for rubella virus. 10 Informed knowledge of rubella viruses circulating in Uganda will enhance efforts to monitor the impact of the vaccination strategy as Uganda moves toward control and elimination of rubella and CRS. 31 
| LIMITATIONS
This study used samples collected during the routine measles surveillance. In Uganda, routine measles surveillance targets children under the age of 15 that present with rash and fever. Therefore, some rubella cases especially the subclinical ones and those above 15
years of age may have been missed.
Secondly, genotyping from sera requires acute phase specimens. This is because the highest viral titers in blood typically occur before rash onset, 14 which makes timing of sample collection critical. In this study, all the specimens that were successfully genotyped had been collected within 2 days of rash onset. Nonetheless, the use of sera is intended to supplement already existing molecular surveillance methods.
In addition, the study used archived samples that had been stored at −20°C (as opposed to the recommended −70°C for preservation of RNA) and could have undergone a series of freeze/thaw cycles. The combination of long storage at −20°C and unknown freeze/thaw cycles may have had a deleterious effect.
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